Targeted Oncology10d
Newly Diagnosed mHSPC: First-Line Treatment Options
Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...
Targeted Oncology10d
Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection
Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate ...
Hosted on MSN1mon
FDA Accepts Bayer's Application for Label Expansion of Nubeqa
The sNDA is seeking label expansion of Nubeqa in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Pharmabiz4d
Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer
Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...
pharmaphorum2d
MHRA, NHS England make available new prostate cancer treatment
Darolutamide + ADT in combination with docetaxel is to be used to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC) and will be immediately available in England for eligible ...
Daily4d
Bayer partner seeks approval for Darolutamide plus androgen deprivation therapy for metastatic hormone sensitive prostate cancer
Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...
Orion’S Collaboration Partner Bayer Submits Application In China For Third Indication Of Darolutamide
Orion's collaboration partner Bayer submits application in China for third indication of darolutamide ...
腾讯网5d
第 3 项！达罗他胺新适应症在国内报上市
1 月 7 日，拜耳宣布已向 CDE 提交口服雄激素受体抑制剂（ARi）达罗他胺的上市申请，与雄激素剥夺疗法（ADT）联合用药，用于治疗转移性激素敏感性前列腺癌（mHSPC）患者。这是该药在中国申报的第 3 ...
腾讯网4d
拜耳诺倍戈第三项适应症注册申请获NMPA受理，实现新适应症全球同步递交
拜耳公司宣布，诺倍戈（达罗他胺）联合雄激素剥夺疗法（ADT）治疗转移性激素敏感性前列腺癌（mHSPC）成年患者的新适应症申请已获国家药品监督管理局（NMPA）药品审评中心（CDE）受理。诺倍戈是口服新一代雄激素受体抑制剂（ARi），已先后获批用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌（NM-CRPC）成年患者，和联 ...